All In Biotech

NDA 207356 · Insmed INC

Arikayce Kit

Amikacin Sulfate · Inhalation · Aminoglycoside Antibacterial

Breakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Sep 28, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

104

24 Phase 3, 13 recruiting

FAERS reports

17,297

14,295 serious, 3,446 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS ARIKAYCE has been associated with an increased risk of respiratory adverse reactions including, hypersensitivity pneumonitis, hemoptysis, bronchospasm, exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases [see Warnings and Precautions (5.1 , 5.2 , 5.3 , 5.4) ] . WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS See full prescribing information for complete boxed warning. ARIKAYCE has been associated with a risk of increased respiratory adverse reactions, including, hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases. ( 5.1 , 5.2 , 5.3 , 5.4 )

What it is approved for

From the label in effect Aug 4, 2026.

LIMITED POPULATION: ARIKAYCE ® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options . This drug is indicated for use in a limited and specific population of patients. This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials . LIMITED POPULATION: ARIKAYCE is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients. ( 1 ) This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3...

Mechanism: ARIKAYCE is an antibacterial drug [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 19, 2020 Supplement 3 · Efficacy OrphanLetterLabel
  • Sep 28, 2018 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • ARIKAYCE KIT · AMIKACIN SULFATE EQ 590MG BASE/8.4ML · SUSPENSION, LIPOSOMAL, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amikacin" as an intervention, any sponsor and status, largest first.

All 104 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,052
  • drug ineffective1,836
  • cough1,733
  • dyspnoea1,666
  • therapy interrupted1,437
  • hospitalisation1,415
  • death1,154
  • dysphonia1,046
  • nausea800
  • product dose omission issue786
  • fatigue781
  • pneumonia703

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004137
2005104
200698
2007134
2008136
2009120
2010146
2011230
2012212
2013220
2014209
2015275
2016408
2017508
2018811
20192,136
20201,812
20211,453
20221,387
20231,869
20242,088
20251,781
20261,023

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 685 on PubMed

Sponsor: Insmed INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.